Promising results of amivantamab studies appear in high-profile journals

Wednesday, March 13, 2024

Multiple studies at Providence Cancer Institute of Oregon are evaluating amivantamab alone and in combination with other agents in people with non-small cell lung cancer (NSCLC). Amivantamab is a novel bi-specific antibody that has shown promise as an effective agent in treating NSCLC that has certain epidermal growth factor receptor (EGFR) mutations and MET alterations in recent trials, including the phase III MARIPOSA-2 study. The results of MARIPOSA-2 were published at the 2023 European Society of Medical Oncology meeting, in the Annals of Oncology.

“The combination treatment has not received FDA approval at this time, and the overall survival of patients is pending, but the study shows that adding amivantamab to chemotherapy after a targeted therapy helped control these cancers for longer than with chemotherapy alone,” said Rachel Sanborn, M.D., medical director, Providence Thoracic Oncology Program and the Phase I Clinical Trials Program at Providence Cancer Institute. Dr. Sanborn was principal investigator of the trial.

In a phase I study known as CHRYSALIS, amivantamab was given with lazertinib, an EGFR tyrosine kinase inhibitor, to patients with NSCLC EGFR mutations. At mid-study assessment, the safety and feasibility of the amivantamab and lazertinib regimen was approved for phase II dose evaluation. The initial results of CHRYSALIS were recently published in Nature Medicine. Dr. Sanborn is a co-author of the study.

A phase III study published in The New England Journal of Medicine in October 2023, showed the combination of amivantamab plus chemotherapy resulted in superior efficacy as compared with chemotherapy alone as a first-line treatment in people with advanced NSCLC with epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The study was co-authored by Dr. Sanborn, who also served on the steering committee. Although unable to match patients to the study criteria required for enrollment, Providence Cancer Institute provided input on the study.

Learn more about Providence Cancer Institute of Oregon.

To see current and past studies visit:    